摘要
目的:探讨手术后分化型甲状腺癌131I清甲治疗的临床疗效及影响因素。方法:对376例分化型甲状腺癌患者行131I治疗,并进行2-10年随访,以全身131I扫描,甲状腺摄131I率、血清TG浓度来评判清甲治疗疗效。结果:376例患者中266例1次131I消融成功,1次成功率70.74%。1次消融有效病例333例,有效率为88.56%。消融无效病例43例,无效率11.44%。不同病理类型间一次消融率无统计学差异,不同治疗时间一次消融成功率有统计学差异。结论:甲状腺外科手术+131I+TSH抑制治疗的综合治疗方法在分化型甲状腺癌的治疗中有重要作用,外科手术方式和手术后到131I治疗时间是疗效的重要影响因素。
Objective： To study the efficacy of the first radioactive iodine （ 131 I） ablation of residual thyroid tissue on differentiated thyroid carcinoma （DTC） after surgery and to analyze the influential factors and efficacy. Methods： All 376 patients with differentiated thyroid carcinoma after surgery were treated by 131 I. They were followed up for two -ten years after ablation. The 131I -whole -body -scan, 131I uptake ration and the level of thyroglobulin （TG） were the evaluation standards for successful ablation. Results： Of 376 patients 266 （ 70.74% ） had successful ablation of re- sidual thyroid tissue after the first radioactive iodine （131 I） ablation. Effective treatment was achieved in 333 patients （88.56%） and treatment failure in 73 cases （11.44% ）. Pathological types had no statistically effect on the first radi- oaetive iodine （ 131 I） ablation. Conclusion： The combined treatment of thyroidectomy, radioiodine therapy and TSH suppression is the effective method in differentiated thyroid carcinoma （DTC） management. It is playing an important role in the clinical practice. Surgical operation and the time after surgery to the ablation are the primary influencing factors in the differentiated thyroid cancer.
出处
《现代肿瘤医学》
CAS
2013年第10期2209-2211,共3页
Journal of Modern Oncology
关键词
分化型甲状腺癌
131I清甲治疗
甲状腺球蛋白
differentiated thyroid carcinoma （ DTC ）
radioactive iodine （ 131 I） ablation
thyroglobulin （TG）
